View Older Stories View More Recent Stories

Nov 1, 2018 10:36AM Multiple Abstracts Highlighting Data from Incyte’s Targeted Therapy Portfolio Accepted for Presentation at the 60th Annual ASH Meeting
Oct 30, 2018 07:00AM Incyte Reports 2018 Third Quarter and Nine Month Financial Results and Provides Updates on Key Clinical Programs
Oct 25, 2018 02:14PM Incyte Named a 2018 Top Employer by Science Magazine
Oct 25, 2018 07:39AM Incyte (INCY) Granted FDA Priority Review for Ruxolitinib for GVHD
Oct 25, 2018 07:30AM FDA Grants Priority Review for Ruxolitinib (Jakafi®) as a Treatment for Patients with Acute Graft-Versus-Host Disease
Oct 22, 2018 05:43AM Incyte (INCY) Reports Positive Interim Data from Phase 2 Trial of Pemigatinib
Oct 21, 2018 06:30PM ACR 2018: Lilly Shares Updated Safety Analysis of OLUMIANT® (baricitinib) in Patients with Moderately-to-Severely Active Rheumatoid Arthritis
Oct 21, 2018 06:45AM Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma
Oct 19, 2018 10:12AM Incyte (INCY) Reports Phase 2 GEOMETRY Mono-1 Trial of Investigational Medicine Capmatinib Shows Positive Results
Oct 19, 2018 10:10AM Phase 2 GEOMETRY mono-1 Trial of Investigational Medicine Capmatinib Shows Positive Results in Patients with MET-mutated Advanced NSCLC
Oct 11, 2018 08:00AM Incyte to Report Third Quarter Financial Results
Oct 9, 2018 07:30AM Incyte Announces Data for Pemigatinib, its Selective FGFR Inhibitor, to be Featured at the ESMO 2018 Congress
Sep 17, 2018 09:03AM Agenus (AGEN) Secures $5M Milestone Payment from Incyte (INCY) for Initiation of Phase 1 Clinical Trial of INCAGN2385
Sep 13, 2018 09:00AM In Honor of MPN Awareness Day and Blood Cancer Awareness Month, Incyte Debuts Documentary Spotlighting Myeloproliferative Neoplasms (MPNs)
Sep 13, 2018 07:30AM Incyte (INCY) Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis
Sep 13, 2018 07:30AM Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis
Sep 11, 2018 07:36AM Incyte (INCY) Reports Agreement with Foundation Medicine for Development, Regulatory Support & Commercialization of Companion Diagnostic for Pemigatinib (INCB54828)
Sep 11, 2018 07:30AM Incyte and Foundation Medicine Announce Agreement to Develop Companion Diagnostic for Pemigatinib (INCB54828), a Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma
Sep 6, 2018 04:35PM Incyte (INCY) Announces Retirement of CFO David Gryska at the End of 2018
Sep 6, 2018 04:30PM Incyte Announces Chief Financial Officer David Gryska to Retire at the End of 2018
Aug 28, 2018 08:00AM Incyte to Present at Upcoming Investor Conference
Jul 31, 2018 07:00AM Incyte Reports 2018 Second Quarter Financial Results and Updates on Key Clinical Programs
Jul 19, 2018 06:30PM Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE)
Jul 12, 2018 08:00AM Incyte to Report Second Quarter Financial Results
Jun 21, 2018 08:30AM Incyte to Present Diversified Development Portfolio and Opportunities for Accelerated Growth at 2018 Investor and Analyst Event
Jun 21, 2018 07:04AM Incyte (INCY) Announces REACH1 Pivotal Trial Meets Primary Endpoint of ORR for Ruxolitinib in Steroid-Refractory Acute GVHD
Jun 21, 2018 07:00AM Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate for Ruxolitinib (Jakafi®) in Steroid-Refractory Acute Graft-Versus-Host Disease
Jun 1, 2018 12:14PM Eli Lilly & Co. (LLY), Incyte (INCY) Confirm FDA Approval of 2-mg OLUMIANT
Jun 1, 2018 12:04PM FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis
May 24, 2018 08:00AM Incyte to Present at Upcoming Investor Conferences
May 1, 2018 07:00AM Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs
Apr 26, 2018 08:00AM Incyte to Present at Upcoming Investor Conference
Apr 25, 2018 05:38PM Incyte Highlights Abstracts Accepted for Presentation at the 2018 ASCO Annual Meeting
Apr 24, 2018 06:01AM Eli Lilly & Co. (LLY) & Incyte Corporation (INCY) Confirms FDA Advisory Committee Recommends Approval of Baricitinib 2mg and Against 4mg
Apr 23, 2018 08:11PM FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
Apr 13, 2018 08:00AM Incyte to Report First Quarter Financial Results
Apr 6, 2018 07:32AM Incyte (INCY) Phase 3 ECHO-301 Study Didn't Meet Primary Endpoint
Apr 6, 2018 07:30AM Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma
Mar 15, 2018 08:36AM Incyte (INCY) Says Targeted Therapy, Immuno-Oncology Portfolio to be Featured in 15 Abstracts at AACR
Mar 15, 2018 08:35AM Incyte Targeted Therapy and Immuno-Oncology Portfolio to be Featured in 15 Abstracts at the AACR Annual Meeting 2018
Feb 28, 2018 09:00AM Incyte Supports the Myeloproliferative Neoplasm Community in Honor of Rare Disease Day 2018
Feb 20, 2018 08:00AM Incyte to Present at Upcoming Investor Conferences
Feb 15, 2018 07:00AM Incyte Reports 2017 Fourth-Quarter and Year-End Financial Results, Provides 2018 Financial Guidance and Updates on Key Clinical Programs
Feb 6, 2018 08:00AM Incyte to Present at Upcoming Investor Conference
Jan 31, 2018 04:30PM Incyte Updates Conference Call Time to Report Fourth Quarter and Year-End Financial Results
Jan 24, 2018 08:00AM Incyte to Report Fourth Quarter and Year-End Financial Results
Jan 23, 2018 08:00AM Incyte Corporation Recommends Shareholders Reject Mini-Tender Offer by TRC Capital Corporation
Jan 8, 2018 08:04AM Incyte (INCY), Syros (SYRS) Announce Global Target Discovery and Validation Pact Focused on Myeloproliferative Neoplasms
Jan 8, 2018 08:00AM Incyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms
Dec 14, 2017 08:00AM Incyte to Present at Upcoming Investor Conference
View More Recent Stories View Older Stories